+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Amyloidosis Treatment - Global Strategic Business Report - Product Thumbnail Image

Amyloidosis Treatment - Global Strategic Business Report

  • Report
  • August 2025
  • 283 Pages
  • Global
From
Desmopressin - Global Strategic Business Report - Product Thumbnail Image

Desmopressin - Global Strategic Business Report

  • Report
  • August 2025
  • 93 Pages
  • Global
From
DPP-IV Inhibitors - Global Strategic Business Report - Product Thumbnail Image

DPP-IV Inhibitors - Global Strategic Business Report

  • Report
  • August 2025
  • 262 Pages
  • Global
From
Human Growth Hormone Drugs - Global Strategic Business Report - Product Thumbnail Image

Human Growth Hormone Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 335 Pages
  • Global
From
From
Osteoporosis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Osteoporosis Therapeutics - Global Strategic Business Report

  • Report
  • August 2025
  • 340 Pages
  • Global
From
Drugs for Hormonal Replacement Therapy Market Report 2025 - Product Thumbnail Image

Drugs for Hormonal Replacement Therapy Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Diabetic Peripheral Neuropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Peripheral Neuropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Graves' Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Graves' Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 60 Pages
  • Global
From
Batten Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Batten Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 60 Pages
  • Global
From
Metabolic Acidosis - Pipeline Insight, 2025 - Product Thumbnail Image

Metabolic Acidosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Insulin Resistance - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Resistance - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Secondary Hyperparathyroidism - Pipeline Insight, 2025 - Product Thumbnail Image

Secondary Hyperparathyroidism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Porphyria - Pipeline Insight, 2025 - Product Thumbnail Image

Porphyria - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 65 Pages
  • Global
From
Pompe Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Pompe Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Exocrine Pancreatic Insufficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Exocrine Pancreatic Insufficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Idiopathic Short Stature - Pipeline Insight, 2025 - Product Thumbnail Image

Idiopathic Short Stature - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Glucokinase Activators - Pipeline Insight, 2025 - Product Thumbnail Image

Glucokinase Activators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more